Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma

SIMPLE SUMMARY: Immune checkpoint inhibitors are dramatically reshaping cancer treatments in a multitude of advanced cancers, including hepatocellular carcinoma (HCC). However, only a subgroup of patients with HCC currently benefits from immunotherapy. Therefore, we performed a multicenter explorato...

Descripción completa

Detalles Bibliográficos
Autores principales: Spahn, Stephan, Roessler, Daniel, Pompilia, Radu, Gabernet, Gisela, Gladstone, Beryl Primrose, Horger, Marius, Biskup, Saskia, Feldhahn, Magdalena, Nahnsen, Sven, Hilke, Franz J., Scheiner, Bernhard, Dufour, Jean-François, De Toni, Enrico N., Pinter, Matthias, Malek, Nisar P., Bitzer, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766321/
https://www.ncbi.nlm.nih.gov/pubmed/33353145
http://dx.doi.org/10.3390/cancers12123830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766321/
https://www.ncbi.nlm.nih.gov/pubmed/33353145
http://dx.doi.org/10.3390/cancers12123830

Ejemplares similares